The Expanding Landscape of Diabetes Complications: Liver Disease, Cancer, and Frailty

Early in training, many clinicians learn the classic “eye–kidney–foot” framework for recognizing and managing complications of diabetes. However, as science advances, the range of recognized consequences of diabetes—and opportunities for earlier intervention—continues to broaden. Today, the concept of diabetes complications screening must evolve to include conditions such as metabolic dysfunction–associated steatotic liver disease (MASLD), certain cancers, cognitive decline, and frailty. In this article, we discuss how clinicians can update their screening strategies and patient education to reflect these emerging risks.

Table of Contents

• Traditional diabetes complications and the limits of current screening
• Metabolic liver disease: a rising concern
• Cancer risk in people with diabetes
• Cognitive impairment and sarcopenia
• Integrating expanded screening into clinical practice
• Conclusion
• Frequently Asked Questions

Traditional Diabetes Complications and the Limits of Current Screening

For decades, diabetes care has rightly focused on preventing and detecting microvascular and macrovascular complications, such as retinopathy, nephropathy, neuropathy, and cardiovascular disease. Indeed, diabetes complications screening traditionally concentrates on checking A1C levels, monitoring blood pressure, doing foot exams, and ordering eye and urine tests. However, while these remain essential, they do not capture the full spectrum of health challenges faced by people living with diabetes.

Consequently, many clinicians and patients remain unaware of how diabetes may contribute to other serious conditions. For example, liver disease related to metabolic dysfunction, and an elevated risk of several types of cancer, are increasingly documented in peer‑reviewed research. In addition, evidence highlights links between long‑term diabetes, cognitive decline, and frailty—especially as people age. Therefore, expanding the concept of diabetes complications screening is not just academic; it directly influences clinical outcomes and quality of life.

Metabolic Liver Disease: A Rising Concern

One of the most underrecognized complications associated with type 2 diabetes is metabolic dysfunction–associated steatotic liver disease (MASLD). Previously called nonalcoholic fatty liver disease (NAFLD), MASLD encompasses a spectrum from simple fat accumulation in the liver to inflammatory and fibrotic changes that can lead to cirrhosis. Notably, people with diabetes have a markedly higher prevalence of MASLD compared to the general population.

Importantly, early stages of MASLD are often silent. Therefore, unless clinicians consider this diagnosis and use appropriate tests—such as liver enzymes, imaging, and fibrosis scores—it may go undetected until advanced. Because progression to severe liver disease increases morbidity and mortality, integrating MASLD into diabetes complications screening protocols is crucial. Furthermore, referring patients to nutrition and lifestyle support services, as outlined in related DiabetesInControl coverage on liver health, can optimize prevention and management.

Cancer Risk in People With Diabetes

Beyond liver disease, research shows that diabetes is associated with an increased risk of several cancers, including those of the liver, pancreas, endometrium, and colon. Although the mechanisms linking diabetes and cancer are complex, factors such as chronic inflammation, hyperinsulinemia, and shared lifestyle determinants play a role. Therefore, cancer risk assessment should be a routine part of comprehensive diabetes complications screening.

For example, clinicians should ensure adherence to age‑appropriate cancer screening guidelines. Colonoscopy, mammography, and cervical cancer screening are already standard in preventative care, yet explicit linkage to diabetes care conversations may improve uptake. Moreover, for specific populations, enhanced vigilance and possibly earlier screening could be warranted. Because evidence evolves rapidly, health care providers should stay current with guidelines from organizations such as the American Diabetes Association and the American Cancer Society and integrate them into patient care plans.

Cognitive Impairment and Sarcopenia

Another expanding area within diabetes research is the impact of chronic hyperglycemia and vascular changes on brain health. Studies suggest that long‑standing diabetes increases the risk of cognitive decline and dementia. As a result, clinicians should include brief cognitive assessments in routine care, especially in older adults or those reporting memory changes. Such assessments can be part of holistic diabetes complications screening that goes beyond laboratory values alone.

Similarly, sarcopenia—age‑related loss of muscle mass and strength—intersects with diabetes and frailty. People with diabetes are at greater risk for reduced muscle quality, which predisposes them to falls, disability, and loss of independence. Regular assessment of gait, grip strength, and muscle mass can alert clinicians to early changes. When identified, interventions such as tailored exercise prescriptions and nutritional counseling can help mitigate decline.

Integrating Expanded Screening Into Clinical Practice

So how can clinicians incorporate this broader view of complications into everyday practice? First, update patient education materials to include discussion of liver health, cancer risk, cognitive function, and physical resilience. Patients often assume that managing their blood sugar means they are fully protected; however, clear communication about additional risks empowers them to be proactive.

Second, adopt validated tools that support expanded diabetes complications screening. For example, use non‑invasive fibrosis scores for MASLD, implement standardized cognitive screening tools, and record physical performance metrics during visits. Although time constraints in clinic can be challenging, even brief assessments can yield actionable insights.

Third, leverage electronic health record (EHR) systems to prompt necessary screenings and referrals. For instance, set reminders for age‑based cancer screenings or alerts when liver test results are abnormal. Such integration helps ensure that nothing is overlooked in the complexity of managing chronic disease.

Finally, include family members and caregivers in discussions when appropriate. Because many of these emerging complications do not manifest with obvious symptoms early on, support from caregivers can help patients adhere to screening recommendations and lifestyle modifications.

Conclusion

In summary, diabetes care must evolve beyond the traditional “eye–kidney–foot” model to include a broader spectrum of risks. Expanding diabetes complications screening to address liver disease, cancer risk, cognitive impairment, and frailty is essential for comprehensive care. By updating screening protocols, enhancing patient education, and fostering interprofessional collaboration, clinicians can better identify and address the full range of diabetes‑related health challenges. Early detection leads to earlier intervention, improved outcomes, and enhanced quality of life for people living with diabetes.

Frequently Asked Questions

What is included in diabetes complications screening?
Traditional screening includes checks for retinopathy, nephropathy, neuropathy, and cardiovascular risk, and should now include assessments for liver health, cancer risk, cognitive function, and frailty.

How often should liver health be evaluated in people with diabetes?
While individual needs vary, initial liver enzyme testing at diagnosis and periodic monitoring annually or when abnormalities arise is advisable, especially for those with metabolic risk factors.

Can managing blood sugar reduce cancer risk?
Good glycemic control may help reduce inflammation and other cancer‑related risk factors, but regular age‑appropriate cancer screenings remain important regardless of blood sugar levels.

Are there simple tools for cognitive screening in diabetes care?
Yes, brief tools such as the Mini‑Cog or Montreal Cognitive Assessment (MoCA) can be used in clinic to identify early signs of cognitive decline.

What lifestyle changes support prevention of these emerging complications?
Regular physical activity, a balanced diet, weight management, smoking cessation, and routine health screenings all support overall health and may reduce the risk of complications.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.